Drug Type Antibody drug conjugate (ADC) |
Synonyms |
Target |
Action inhibitors |
Mechanism GD3 inhibitors(Ganglioside GD3 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC39H62N6O6S |
InChIKeyQAAFNSMAIAVCHE-BZLYQNAUSA-N |
CAS Registry1436391-86-4 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 1 | - | - | |
Multiple Myeloma | Phase 1 | - | - | |
Unresectable Melanoma | Discovery | United States | 16 May 2017 | |
Unresectable Melanoma | Discovery | United States | 16 May 2017 |